MITI Quote, Financials, Valuation and Earnings

GoodRx Holdings, Inc. has a net margin of -106766.67% compared to Mitesco, Inc.'s net margin of 0.57%. Mitesco, Inc.'s return on equity of -- beat GoodRx Holdings, Inc.'s return on equity of 4.78%.

Mitesco, Inc. has a consensus price target of --, signalling upside risk potential of 247.83%. On the other hand GoodRx Holdings, Inc. has an analysts' consensus of $5.09 which suggests that it could grow by 87.8%. Given that Mitesco, Inc. has higher upside potential than GoodRx Holdings, Inc., analysts believe Mitesco, Inc. is more attractive than GoodRx Holdings, Inc..

Mitesco, Inc. has a beta of 2.522, which suggesting that the stock is 152.243% more volatile than S&P 500. In comparison GoodRx Holdings, Inc. has a beta of 1.470, suggesting its more volatile than the S&P 500 by 47.004%.

Mitesco, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GoodRx Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mitesco, Inc. pays -- of its earnings as a dividend. GoodRx Holdings, Inc. pays out -- of its earnings as a dividend.

Mitesco, Inc. quarterly revenues are $3K, which are smaller than GoodRx Holdings, Inc. quarterly revenues of $196M. Mitesco, Inc.'s net income of -$3.2M is lower than GoodRx Holdings, Inc.'s net income of $1.1M. Notably, Mitesco, Inc.'s price-to-earnings ratio is 2.30x while GoodRx Holdings, Inc.'s PE ratio is 31.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mitesco, Inc. is 28.92x versus 1.24x for GoodRx Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

National Research Corp. has a net margin of -106766.67% compared to Mitesco, Inc.'s net margin of 11.54%. Mitesco, Inc.'s return on equity of -- beat National Research Corp.'s return on equity of 61.55%.

Mitesco, Inc. has a consensus price target of --, signalling upside risk potential of 247.83%. On the other hand National Research Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that Mitesco, Inc. has higher upside potential than National Research Corp., analysts believe Mitesco, Inc. is more attractive than National Research Corp..

Mitesco, Inc. has a beta of 2.522, which suggesting that the stock is 152.243% more volatile than S&P 500. In comparison National Research Corp. has a beta of 0.447, suggesting its less volatile than the S&P 500 by 55.256%.

Mitesco, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. National Research Corp. offers a yield of 3.03% to investors and pays a quarterly dividend of $0.12 per share. Mitesco, Inc. pays -- of its earnings as a dividend. National Research Corp. pays out 45.99% of its earnings as a dividend. National Research Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Mitesco, Inc. quarterly revenues are $3K, which are smaller than National Research Corp. quarterly revenues of $34.6M. Mitesco, Inc.'s net income of -$3.2M is lower than National Research Corp.'s net income of $4M. Notably, Mitesco, Inc.'s price-to-earnings ratio is 2.30x while National Research Corp.'s PE ratio is 22.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mitesco, Inc. is 28.92x versus 2.60x for National Research Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Predictive Oncology, Inc. has a net margin of -106766.67% compared to Mitesco, Inc.'s net margin of -2156852.78%. Mitesco, Inc.'s return on equity of -- beat Predictive Oncology, Inc.'s return on equity of -1065.31%.

Mitesco, Inc. has a consensus price target of --, signalling upside risk potential of 247.83%. On the other hand Predictive Oncology, Inc. has an analysts' consensus of -- which suggests that it could grow by 956.34%. Given that Predictive Oncology, Inc. has higher upside potential than Mitesco, Inc., analysts believe Predictive Oncology, Inc. is more attractive than Mitesco, Inc..

Mitesco, Inc. has a beta of 2.522, which suggesting that the stock is 152.243% more volatile than S&P 500. In comparison Predictive Oncology, Inc. has a beta of 1.354, suggesting its more volatile than the S&P 500 by 35.357%.

Mitesco, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Predictive Oncology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mitesco, Inc. pays -- of its earnings as a dividend. Predictive Oncology, Inc. pays out -- of its earnings as a dividend.

Mitesco, Inc. quarterly revenues are $3K, which are smaller than Predictive Oncology, Inc. quarterly revenues of $3.6K. Mitesco, Inc.'s net income of -$3.2M is higher than Predictive Oncology, Inc.'s net income of -$77.6M. Notably, Mitesco, Inc.'s price-to-earnings ratio is 2.30x while Predictive Oncology, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mitesco, Inc. is 28.92x versus 13.06x for Predictive Oncology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Spok Holdings, Inc. has a net margin of -106766.67% compared to Mitesco, Inc.'s net margin of 9.46%. Mitesco, Inc.'s return on equity of -- beat Spok Holdings, Inc.'s return on equity of 10.88%.

Mitesco, Inc. has a consensus price target of --, signalling upside risk potential of 247.83%. On the other hand Spok Holdings, Inc. has an analysts' consensus of $20.00 which suggests that it could grow by 61.29%. Given that Mitesco, Inc. has higher upside potential than Spok Holdings, Inc., analysts believe Mitesco, Inc. is more attractive than Spok Holdings, Inc..

Mitesco, Inc. has a beta of 2.522, which suggesting that the stock is 152.243% more volatile than S&P 500. In comparison Spok Holdings, Inc. has a beta of 0.438, suggesting its less volatile than the S&P 500 by 56.19%.

Mitesco, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spok Holdings, Inc. offers a yield of 9.6% to investors and pays a quarterly dividend of $0.31 per share. Mitesco, Inc. pays -- of its earnings as a dividend. Spok Holdings, Inc. pays out 171.77% of its earnings as a dividend.

Mitesco, Inc. quarterly revenues are $3K, which are smaller than Spok Holdings, Inc. quarterly revenues of $33.9M. Mitesco, Inc.'s net income of -$3.2M is lower than Spok Holdings, Inc.'s net income of $3.2M. Notably, Mitesco, Inc.'s price-to-earnings ratio is 2.30x while Spok Holdings, Inc.'s PE ratio is 16.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mitesco, Inc. is 28.92x versus 1.93x for Spok Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.